Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436) Fair Value & Analysis
Healthcare · CN · Market cap 72.1B CNY
Fair value as of: Jul 11, 2026
From 17 valuation models · updated 27 days ago
Fair value updated Jul 11, 2026, revised from ¥64.03 to ¥60.82 (−5.0%) since Jun 24, 2026. Share price +22.5% over the past month.
A solid business, but screening 55% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥76.03). The favourable scenario is already priced in.
- Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥33.36 to ¥76.03) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 11, 2026.
How to read this chart
60‑month range ¥108.00 – ¥485.80 · fair‑value band ¥33.36 – ¥76.03 · the ¥135.79 price screens above the ¥60.82 fair value. Dashed = 300-day average. As of Jul 11, 2026.
Analysis
Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436) currently trades at ¥135.79, while our model-based Fair Value estimate is ¥60.82, implying the stock looks roughly 55.2% overvalued today. We read business quality at 50/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Zhangzhou Pientzehuang Pharmaceutical., Ltd generated revenue of 8.6B CNY at a net margin of 22.1%. Revenue declined 12.7% year over year. It earns a return on equity of 11.8%. The balance sheet holds a net cash position of 382M CNY. Fundamentals as of Jul 11, 2026
Our scenario range runs from ¥33.36 (bear case) to ¥76.03 (bull case); at ¥135.79, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -55%, 600436 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: DCF Models (¥96.16) versus Asset-Based (¥16.15). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zhangzhou Pientzehuang Pharmaceutical., Ltd., together with its subsidiaries, manufactures and distributes pharmaceuticals and cosmetics in China and internationally.
Full company description
Zhangzhou Pientzehuang Pharmaceutical., Ltd., together with its subsidiaries, manufactures and distributes pharmaceuticals and cosmetics in China and internationally. The company offers traditional Chinese medicines and health products in various forms, including capsule, ointment, tablet, syrup, and pill; health care food and functional drinks; special efficacy cosmetics; and household chemicals under the Pien Tze Huang brand name. It is also involved in the sale of food; production of skin, hair, and oral care daily products; biotechnology and medical device research and development; sale of medical machinery; and online wholesale and retail. The company's products are used for liver diseases, cardiovascular and cerebrovascular, cancer, cold, dermatology, and other applications. It exports its products. The company was founded in 1956 and is based in Zhangzhou, China. Zhangzhou Pientzehuang Pharmaceutical., Ltd. operates as a subsidiary of Zhangzhou Jiulongjiang Group Co., Ltd.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhangzhou Pientzehuang Pharmaceutical., Ltd reported revenue of ¥9.0B in FY2025 versus ¥8.0B in FY2021, a compound +2.9%/yr. Reported net income was ¥2.2B in FY2025, compounding −2.9%/yr from FY2021.
600436 screens 55% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 75 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,182 | $396.77 | -66% |
| Johnson & Johnson, JNJ | $257.59 | $169.04 | -34% |
| AbbVie Inc ABBV | $254.49 | $67.72 | -73% |
| Roche Holding 1RO | €377.80 | €280.03 | -26% |
| Merck & Co MRK | €108.08 | €121.54 | +12% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| AstraZeneca PLC AZN | $171.61 | $129.54 | -25% |
| Novo Nordisk A/S NOVOB | kr 329.90 | kr 409.46 | +24% |
| Amgen Inc AMGN | $363.39 | $252.02 | -31% |
| Gilead Sciences, Inc GILD | $134.28 | $146.50 | +9% |
Compare Zhangzhou Pientzehuang Pharmaceutical., Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436) overvalued or undervalued?
What is the fair value of 600436?
What is the quality score of 600436?
What is the revenue of Zhangzhou Pientzehuang Pharmaceutical., Ltd (600436)?
What is the net profit margin of 600436?
Does Zhangzhou Pientzehuang Pharmaceutical., Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zhangzhou Pientzehuang Pharmaceutical., Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.